Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytodyn Inc (OP:CYDY)

0.2590 +0.0051 (+2.01%)
Streaming Delayed Price Updated: 11:35 AM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 513,943
Open 0.2550
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.2539
Today's Range 0.2516 - 0.2748
52wk Range 0.1031 - 0.4945
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Halper Sadeh LLC Encourages CytoDyn Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
CytoDyn to Present at the LD Micro Main Event XIX Investor Conference
From CytoDyn Inc.
Via GlobeNewswire

Performance

YTD
+122.3%
+122.3%
1 Month
-7.5%
-7.5%
3 Month
-10.7%
-10.7%
6 Month
+8.6%
+8.6%
1 Year
+84.1%
+84.1%

More News

Read More
September 2025 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity
From CytoDyn Inc.
Via GlobeNewswire
A Penny Stock To Watch In Challenging Cancer Space
Via Benzinga
CytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Releases ESMO Breast Cancer Meeting Poster
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany
From CytoDyn Inc.
Via GlobeNewswire
When Penny Stocks Can Become Compelling: A Long-Term Buy With CYDY
Via Talk Markets
Topics Stocks / Equities
FDA Advisory Committee Shakeup and Implications for Capricor Therapeutics
Via Talk Markets
Topics Government Stocks / Equities
March 2025 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories
From CytoDyn Inc.
Via GlobeNewswire
December 2024 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques
From CytoDyn Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Cytodyn Inc publicly traded?
Yes, Cytodyn Inc is publicly traded.
What exchange does Cytodyn Inc trade on?
Cytodyn Inc trades on the OTC Traded
What is the ticker symbol for Cytodyn Inc?
The ticker symbol for Cytodyn Inc is CYDY on the OTC Traded
What is the current price of Cytodyn Inc?
The current price of Cytodyn Inc is 0.2590
When was Cytodyn Inc last traded?
The last trade of Cytodyn Inc was at 10/23/25 11:35 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.